Tumor FAK supports fibrillar collagen expression in ovarian cancer ascites. (PubMed, Matrix Biol) - Sep 18, 2026 - "In primary HGSOC ascites samples, FAK inhibitor (IN10018 or VS-4718) or FAK protein degrader (PROTAC) treatment selectively reduced COL1A1, COL3A1, and COL5A2 mRNA levels in tumor cells. Further, human OVCAR8 spheroid COL1A1, COL3A1, and COL5A2 mRNA and spheroid structure were significantly impacted by FAK inhibition and blocking anti-α1 or anti-β1 integrin antibodies. As elevated PTK2 and COL3A1 expression correlate with poor ovarian cancer patient survival, and FAK, α1, and β1 integrin inhibition reduced spheroid COL3A1 protein levels, our findings support a feed-forward linkage whereby FAK regulates fibrillar collagen acting in part via collagen binding integrins supporting HGSOC tumorsphere survival and metastatic spread."
Journal • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • Targeted Protein Degradation • COL1A1 • COL3A1 • COL5A2
|
|
Antonia Boyer; David D Schlaepfer; Dwayne G Stupack; Jyrki Heino; Marjaana Ojalill; Michael T McHale; Pekka Rappu; Safir Ullah Khan; Terrance J Haanen; Ujjwal Suwal; Xiao Lei Chen; Yichi Zhang
|